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Abstract 
SNAI1 is widely regarded as a master driver of epithelial-mesenchymal transition (EMT) and associated with 
breast cancer progression and metastasis. This pro-malignant role is strongly linked to posttranslational 
modification, especially phosphorylation, which controls its protein levels and subcellular localization. While 
multiple kinases are implicated in regulation of SNAI1 stability, the precise mechanism by which SNAI1 is 
stabilized in tumors remains to be fully elucidated. 
Methods: A series of in vitro and in vivo experiments were conducted to reveal the regulation of SNAI1 by 
Serine/Threonine Kinase 39 (STK39) and the role of STK39 in breast cancer metastasis. 
Results: We identified STK39, a member of Stem 20-like serine/threonine kinase family, as a novel 
posttranslational regulator that enhances the stability of SNAI1. Inhibition of STK39 via knockdown or use of a 
specific inhibitor resulted in SNAI1 destabilization. Mechanistically, STK39 interacted with and phosphorylated 
SNAI1 at T203, which is critical for its nuclear retention. Functionally, STK39 inhibition markedly impaired the 
EMT phenotype and decreased tumor cell migration, invasion, and metastasis both in vitro and in vivo. These 
effects were rescued by ectopic SNAI1 expression. In addition, depletion of STK39 dramatically enhanced 
sensitivity to chemotherapeutic agents. 
Conclusions: Our study demonstrated that STK39 is a key mediator of SNAI1 stability and is associated with 
the pro-metastatic cellular process, highlighting the STK39-SNAI1 signaling axis as promising therapeutic 
targets for treatments of metastatic breast cancer. 
Key words: STK39, SNAI1, EMT, phosphorylation, stabilization 
Introduction 
Approximately 90% of cancer deaths are caused 
by metastasis [1]. Metastatic progression spans four 
distinct steps: invasion, intravasation, extravasation 
and metastatic colonization [2,3]. The development of 
invasive capability arises from loss of apical-basal 
polarity and intercellular adhesion in tumor cells. 
These features are reminiscent of events that occur 
during EMT, considered a key step during the 
progression of tumor metastasis [4,5]. Extensive 
studies revealed that the metastasis-linked EMT is 
controlled by a complex network of transcription 
factors (TFs), including the SNAI1/SLUG family [6], 
TWIST [7], δEF1/ZEB1 and SIP1/ZEB2 [8,9]. Hence, a 
better understanding of how these TFs regulate tumor 
metastasis at molecular levels is critical. 
SNAI1, a zinc-finger containing transcription 
factor, induces EMT by direct suppression of 
E-cadherin (CDH1) transcription during development 
or tumor progression [6]. Studies by us and others 
demonstrated that SNAI1 expression correlates with 
tumor grade and predicts a poor patient outcome 
[10-13]. SNAI1 induces resistance to apoptosis, 
confers tumor recurrence, generates breast cancer 









glycolysis [14-16]. Interestingly, SNAI1 is tightly 
controlled at both transcriptional and protein levels. 
Many growth factors and cytokines can 
transcriptionally regulate SNAI1 expression [17]. In 
addition, SNAI1 is a liable protein, degraded by the 
ubiquitin-proteasome pathway, despite constitutive 
mRNA expression. Currently, a number of 
F-box-containing protein ubiquitin ligases are 
implicated in the regulation of SNAI1 degradation 
through kinase-dependent phosphorylation signaling 
cascades. For example, GSK3β phosphorylates SNAI1 
and induces nuclear export, which facilitates β-TRCP- 
mediated ubiquitination-dependent degradation [12]. 
Meanwhile, other kinases enhance the stability of 
SNAI1 by inducing nuclear import, nuclear retention 
or blocking its ubiquitination degradation [18-20]. 
These different types of phosphorylation govern the 
flexibility and reversibility of SNAI1-mediated EMT. 
Despite the number of kinases being linked to 
SNAI1 stability [18-23], an expanded understanding 
of the molecular mechanisms that underlie SNAI1 
phosphorylation and degradation is needed. In the 
current study, we assessed the role of STK39 in SNAI1 
stability. As a member of STE20-like kinases family, 
STK39 holds a putative nuclear localization signal and 
a caspase cleavage site [24]. Full-length STK39 
exhibits diffuse localization under unstimulated 
conditions whereas the caspase-cleaved STK39 is 
located in the nucleus [25]. STK39 has been studied for 
its role in multiple physiological processes, including 
regulation of chloride and water transport [26], cell 
transformation and proliferation [25], and cell 
differentiation [27]. Notably, STK39 regulates these 
physiological processes by phosphorylation-mediated 
activation [24]. In human cancer, STK39 expression is 
elevated and positively correlated with the adverse 
tumor stage and poor prognosis in the non-small cell 
type lung cancer and osteosarcoma [28,29]. STK39 is 
also implicated in regulation of tumor cell 
proliferation, migration and invasion in multiple 
cancers, including osteosarcoma and cervical cancer 
[28,30,31]. However, the molecular mechanism that 
activates the pro-tumorigenic role of STK39 remains 
largely unknown. 
Here, we demonstrate that STK39 interacts with 
and promotes SNAI1 stability by increasing its 
nuclear retention. Our results also show that 
depletion of endogenous STK39 leads to degradation 
of SNAI1, suppression of EMT and metastasis, which 
suggests that STK39 is essential for induction of EMT. 
In addition, depletion of STK39 impacts tumor cell 
sensitivity to chemotherapeutic agents. Overall, our 
data uncovers a novel mechanism for a STK39-SNAI1 
axis in EMT and further underscores STK39 as a 
promising therapeutic target for breast cancer 
treatment. 
Methods 
Plasmids and Reagents 
The WT-STK39, KR-STK39 and CA-STK39 were 
from Jim McCormick (OHSU) and James 
Wohlschlegel (UCLA). Plasmids of wild-type and 
deletion mutants for SNAI1 were generated as 
described [32]; all sequences were verified by DNA 
sequencing. Antibodies purchased from Sigma- 
Aldrich (St. Louis, MO) include: anti-Flag (F3165), 
1:4000; anti-Actin (A2228), 1:10000; anti-Myc (9E10), 
1:3000. Anti-STK39 (2281), 1:1000; anti-SNAI1 (3879), 
1:1000; and α–Tubulin (2144), 1:1000 were from Cell 
Signaling (Danvers, MA). N-cadherin (05-915), 1:1000 
was from Upstate (Lake Placid, NY). Anti-HA (3F10), 
1:10000 was from Roche (Madison, WI) and 
anti-CDH1 (610181), 1:1000 was from BD Bioscience 
(San Jose, CA). Anti-Lamin A/C (sc-376248), 1:1000 
was from Santa Cruz (Dallas, TX). The p-T203-SNAI1 
antibody was from Dr. Greg Longmore. STK39 
shRNA expression plasmids were purchased from 
MISSION shRNA at Sigma-Aldrich. TGFβ1 was from 
Peprotech. STOCK2S 26016 (STO) was from Tocirs 
(Minneapolis, MN) and MG132 was from Sigma. 
Cell Culture 
The human embryonic kidney HEK293, breast 
cancer MCF7, MDA-MB-231, MDA-MB-157 cell lines 
were purchased from the American Type Culture 
Collection (Manassas, VA) and grown in Dulbecco's 
modified Eagle’s/F12 medium plus 10% fetal bovine 
serum as described previously [32]. The breast cancer 
cell line T-47D, was grown in RPMI1640 plus 10% 
FBS. SUM 149 cells were maintained in Ham's F-12 
(Invitrogen, Carlsbad, CA) supplemented with 5% 
FBS, 5 μg/mL insulin, and 1 μg/mL hydrocortisone 
(Sigma). MCF10A cells were maintained in Dulbecco's 
modified Eagle’s medium-F12 (DMEM/F12) 
supplemented with 5% horse serum (Invitrogen, 
16050122), 1% penicillin/streptomycin (Invitrogen, 
15140122), 0.5 μg/ml hydrocortisone (Sigma, H-0888), 
100 ng/ml cholera toxin (Sigma, C-8052), 10 μg/ml 
insulin (Sigma, I-1882), and 20 ng/ml recombinant 
human EGF (Peprotech, 100-15). All the cells lines 
were routinely checked for morphological and growth 
changes to probe for cross-contaminated, or 
genetically drifted cells. If any of these features 
occurred, we use the Short Tandem Repeat profiling 
service by ATCC to re-authenticate the cell lines. 
Invasion and Migration Assay 
Invasion and migration assays were performed 
in Boyden chambers coated with (invasion) or 





without Matrigel (Migration) as instructed by the 
manufacturer (BD biosciences). Cancer cell lines were 
seeded on the top of the upper chamber while the 
bottom chamber was filled with serum-free culture 
medium plus 100 nM lysophosphatidic acid. The 
invasive cancer cells were stained with crystal violent. 
All experiments were performed in triplicate. 
Immunoprecipitation and Western Blotting 
For protein extraction, 5 × 105 cells per well were 
plated onto six-well plates and transiently transfected 
with the indicated expression plasmids. At 48 h 
post-transfection, cells were incubated with or 
without the proteasome inhibitor MG132 (10 μM) for 
an additional 6 h before protein extraction and 
western blot analysis. Primary antibodies against 
Flag, HA, SNAI1 or STK39 were used for protein 
detection. For immunoprecipitation, HEK293T cells 
transfected with the indicated expression plasmids 
were lysed in buffer (50 mM Tris (pH 7.5; 150 mM 
NaCl; 5 μg/ml aprotinin; 1 μg/ml pepstatin; 1% 
Nonidet P-40; 1 mM EDTA and 0.25% deoxycholate). 
Total cell lysates were incubated overnight with 1 μg 
of anti-HA or anti-Flag antibody conjugated to 
agarose beads (Roche) at 4 °C. Lysis buffer washed 
beads were immunoprecipitated and protein 
complexes resolved by 10% SDS–PAGE. The western 
blot was quantified with Image J and normalized with 
internal loading control (Actin). 
Immunofluorescence Staining 
For immunofluorescence microscopy, cells were 
grown on cover slips, fixed with 4% 
paraformaldehyde and incubated overnight with 
anti-Myc, anti-CDH1 or anti-N-cadherin antibody. 
Proteins were visualized by incubation with goat 
anti-mouse conjugated with Alexa Fluor 568 
(Invitrogen). Finally, cover slips were incubated with 
4′, 6′-diamidino-2-phenylindole (Sigma-Aldrich) for 
20 min and visualized under a fluorescent 
microscope. 
Cell proliferation assay 
CCK8 proliferation assays (Takara, Japan) were 
performed to determine the effect of STK39 on 
proliferation. Transfected cells were seeded in 96-well 
plates, and cultured at 37 °C in a 5% CO2 humidified 
atmosphere. At selected time points, 10 μL CCK-8 
solution was added and cells incubated for 2-4 h at 37 
°C. To calculate the number of viable cells, the 
staining intensity was measured as an absorbance at 
450 nm. Results are presented as the means ± standard 
deviation (SD). Data were based on three independent 
experiments. 
Quantitative Real-Time PCR 
Total RNA was isolated using RNeasy Mini kit 
(Qiagen, Valencia, CA) according to the 
manufacturer’s instructions. Specific quantitative 
real-time PCR experiments were performed using 
SYBR Green Power Master Mix following 
manufacturer’s protocol (Applied Biosystems, Foster 
City, CA). 
Soft Agar Colony Formation Assay 
MDA-MB-231 and MDA-MB-157 cells were 
pretreated with paclitaxel (PTX), and STO alone or in 
combination for 48 h. Treated cells were washed and 
grown in a 24-well plate containing 250 µl of 0.3% 
agarose in complete medium without drug. Fresh 
complete medium was replenished every 2 days for a 
total of 12-15 days. Agarose-embedded cell colonies 
were stained with 1 mg/ml of Cell Stain Solution 
overnight. Cell colony formation was quantified using 
Image J software. 
In vivo Tumorigenesis and Metastasis Assay 
Female SCID mice (6-8 week old) were 
purchased from Taconic (Germantown, NY) and 
maintained under specific pathogen-free conditions. 
All procedures were approved by the Institutional 
Animal Care and Use Committee at the University of 
Kentucky and conform to the legal mandates and 
federal guidelines for the care and maintenance of 
laboratory animals. MDA-MB-231-luc cells and 
corresponding clones with knockdown of STK39 
expression were injected via tail vein into 6-week-old 
female SCID mice. Lung metastasis was monitored by 
the IVIS bioluminescence imaging system. Data were 
analyzed using the Student’s t-test; a p value <0.05 
was considered significant. 
Survival Analyses 
For each patient in a data set, a score was 
calculated as the sum of the products of log2 
transformed expression values of STK39. Using 
maximally selected rank statistics (R package 
maxstat), optimal cut-offs for classification of patients 
into high-risk or low-risk groups were calculated for 
each data set. A log-rank test was used to assess the 
Kaplan Meier survival curves and evaluate statistical 
significance in OS between risk groups. A p-value of 
<0.05 was considered statistically significant. The R 
packages survival and survminer were used for these 
calculations and for data visualization. All statistical 
tests were performed using R 3.4.2. 
Statistical Analyses 
Differences between two independent groups 
were calculated using Student’s t-test, or one-way 





ANOVA and Tukey test for multiple comparisons as 
indicated in the figure legends. P values less than 0.05 
were considered statistically significant and are 
denoted as follows: *<0.05, **<0.01, and ***<0.001. All 
data were analyzed with GraphPad Prism 5 software. 
Results 
STK39 stabilizes SNAI1 
As previously reported [33], by purifying SNAI1 
complexes from nuclear extracts of 20 liters HeLa S3 
cells expressing Flag-SNAI1 and subsequent 
top-down mass spectrometry analysis [32], we noticed 
that STK39 was one of the proteins involved in this 
complex (data not shown). To investigate the 
relationship of these two proteins, we co-expressed 
SNAI1 with STK39 in HEK293T cells. Expression of 
wild-type (WT) STK39 stabilized SNAI1. A 
catalytically inactive STK39 harboring the K104R 
mutation (KR), which functions as a dominant- 
negative inhibitor of endogenous STK39 [34,35], 
showed no such effect. However, the constitutively 
active mutant STK39 kinase (T243E/S383D, CA) 
dramatically increased SNAI1 expression, which 
indicates that the enzymatic activity of STK39 is 
required for SNAI1 stabilization (Figure 1A). Both 
STK39 WT and CA also increased endogenous SNAI1 
protein levels in T-47D cells, which contain little 
endogenous SNAI1 (Figure 1B). We then treated 
several breast cancer cells with the STK39 inhibitor 
STOCK2S 26016 (STO). STO treatment dramatically 
reduced the SNAI1 expression (Figure 1C). Consistent 
with this, knockdown of endogenous STK39 resulted 
in a rapid loss of endogenous SNAI1 protein, but had 
no effect on mRNA levels, in MDA-MB-231, MDA- 
MB-157 and SUM 149 cells (Figures 1D and 1E). To 
rule out the off-target effect of shRNA, we rescued 
STK39 expression with shRNA-resistant STK39 in 
shRNA-mediated knockdown MDA-MB-157 cells. As 
we expected, ectopic expression of STK39 restored the 
SNAI1 expression (Figure 1F). Together, our results 
indicate that STK39 stabilizes SNAI1. 
STK39 enhances SNAI1 protein stability by 
blocking SNAI1 degradation 
Because SNAI1 is a liable protein and readily 
degraded by proteasome degradation and because 
STK39 stabilizes SNAI1 but has no effect on mRNA 
 
Figure 1. STK39 stabilizes SNAI1. (A) Flag-SNAI1 was co-expressed with Myc-tagged STK39 (either wild-type (WT), catalytically inactive KR (K104R), or constitutively 
active (CA) mutant) in HEK293T cells. Expression of SNAI1 and STK39 were assessed by western blot with Flag and Myc antibodies, respectively. (B) WT-STK39 or CA-STK39 
was stably transfected into T-47D cells. Lysates were analyzed by western blot. (C) Cells were treated with 10 µM STOCK2S 26016 (STO) for 24 h. Lysates were analyzed by 
western blot. (D) The protein expression of STK39 and SNAI1 from MDA-MB-231, MDA-MB-157, and SUM 149 cells transfected with control or two individual STK39 shRNAs 
was analyzed by western blot. (E) MDA-MB-231, MDA-MB-157 and SUM149 cells were transfected with control or two individual STK39 shRNAs. The mRNA was detected 
by real-time PCR. ** P<0.01, *** P<0.001, compared with controls. (F) The protein expression of STK39 and SNAI1 from MDA-MB-157 cells stably transfected with control, 
STK39 shRNA or STK39 shRNA with shRNA-resistant STK39 (STK39-shR) were analyzed by western blot. 





expression, we asked whether STK39 blocked SNAI1 
degradation. First, we treated STK39 knockdown cells 
with proteasome inhibitor MG132 and found that the 
downregulation of SNAI1 in STK39-knockdown 
MDA-MB-231 cells was restored by MG132 treatment 
(Figure 2A), which indicates that STK39-knockdown 
facilitates the degradation of SNAI1. Consistent with 
this, MG132 treatment also restored the SNAI1 
expression in STO-treated MDA-MB-231 and 
MDA-MB-157 cells (Figure 2B). We then co-expressed 
SNAI1 with STK39 or vector control in HEK293T cells 
and examined SNAI1 degradation. After treatment 
with cycloheximide (CHX) to block new protein 
synthesis, SNAI1 degraded rapidly in cells transfected 
with a control vector (Figures 2C-2D). However, 
SNAI1 levels were stabilized in the presence of STK39 
and this effect continued for up 4 h in the presence of 
CHX. To test whether endogenous SNAI1 is also 
subjected to similar regulation by STK39, we knocked 
down endogenous STK39 in MDA-MB-231 cells, and 
found that endogenous SNAI1 became unstable and 
degraded rapidly (Figures 2E-2F). Since p38, which is 
activated by STK39 [25], was shown to control SNAI1 
expression [18], we examined whether STK39 
stabilizes SNAI1 through downstream effects in the 
p38 pathway. Inhibition of p38 by SB203580 resulted 
in down-regulation of SNAI1 expression [18]. 
However, a similar treatment had no effect on SNAI1 
expression enhanced by STK39, indicating that the 
increase induced by STK39 is p38 independent 
(Figure S1A). To further test whether STK39 blocks 
the interaction between SNAI1 and GSK3β, we 
performed an immunoprecipitation with or without 
STK39. SNAI1 and GSK3β associated to a similar 
extent in the presence or absence of STK39 (Figure 
S1B). Taken together, these results suggest STK39 




Figure 2. STK39 blocks SNAI1 degradation. (A) Protein expression of STK39 and SNAI1 from MDA-MB-231 cells stably transfected with control or two individual STK39 
shRNAs and treated with or without 10 μM MG132 for 8 h was analyzed by western blot. (B) Cells were pre-treated with 10 µM STO for 1 h then treated with or without 10 
μM MG132 for 8 h. Lysates were analyzed by western blot. (C) Flag-SNAI1 was co-expressed with vector or Myc-STK39 in HEK293T cells. After treatment with cycloheximide 
(CHX) for the indicated time intervals, expression of SNAI1 and STK39 was analyzed by western blot using Flag and Myc antibodies, respectively. Presented data are 
representative of 3 separate experiments. (D) The intensity of SNAI1 expression for each time point in (C) was quantified by densitometry and plotted. (E) MDA-MB-231 cells 
were transfected with control or STK39 shRNA. After treatment with CHX as indicated above, expression of endogenous SNAI1 and STK39 was analyzed by western blot. 
Presented data are representative of 3 separate experiments. (F) The intensity of SNAI1 expression for each time point in (E) was quantified by densitometry and plotted. * 
P<0.05, ***P<0.001, compared with controls. 






Figure 3. STK39 interacts with and phosphorylates SNAI1 at T203. (A) HA-SNAI1 was co-expressed with vector or Myc-STK39 in HEK293T cells. SNAI1 and STK39 
were immunoprecipitated (IP) with HA or Myc antibody, respectively, and the associated STK39 and SNAI1 were analyzed by western blot using either Myc or HA antibody. 
One-fortieth of the lysate from each sample was subjected to western blot to examine the expression of SNAI1 and STK39 (input lysate). (B) Endogenous SNAI1 and STK39 
were captured by IP from MDA-MB-231 and MDA-MB-157 cells, and bound endogenous STK39 and SNAI1 were examined by western blot. (C) GFP-SNAI1 was co-expressed 
with Myc-STK39 in HEK293 cells. After fixation, the cellular location of SNAI1 (green) and STK39 (red) was examined by immunofluorescent staining using anti-Myc antibody and 
visualized by fluorescence microscopy (nuclei were stained with DAPI; blue) (left panel). Nuclear SNAI1 was quantified (right panel). *** P<0.001, compared with vector. (D) Cell 
lysates prepared from T-47D cells were transfected with vector or constitutively active (CA)-STK39 and fractioned to identify the location of SNAI1 and STK39. (E) Myc-STK39 
was co-expressed with Flag-tagged wild-type or different mutants of SNAI1 in HEK293T cells. Protein expressions of STK39 and SNAI1 were analyzed by western blot. (F) 
Myc-STK39 WT or KR was co-expressed with Flag-tagged wild type (WT) or T203A of SNAI1 in HEK293T cells. Protein expressions of STK39 and SNAI1 were analyzed by 
western blot. (G) Flag-SNAI1 WT or Flag-SNAI1 T203A was co-transfected with or without Myc-STK39 into HEK293T cells, then treated with MG132 for 6 h. Cell lysates were 
immunoprecipitated using anti-Flag antibody and analyzed by immunoblotting using a specific antibody against pT203-SNAI1. (H) MDA-MB-231 and MDA-MB-157 cells were 
transfected with control or STK39 shRNA. Cells were treated with MG132 for 6 h. Cell lysates were immunoprecipitated using anti-SNAI1 antibody and then analyzed by 
immunoblotting using a specific antibody against pT203-SNAI1. 
 
STK39 interacts with SNAI1 and 
phosphorylates SNAI1 on T203 
To delineate the interaction of STK39 with 
SNAI1, we co-expressed Myc-STK39 and HA-SNAI1 
in HEK293T cells and performed a co-immuno-
precipitation (IP) experiment. After IP of SNAI1, we 
detected an associated STK39, and vice versa (Figure 
3A). IP of endogenous SNAI1 and STK39 from MDA- 
MB-231 and MDA-MB-157 cells also demonstrated the 
presence of endogenous STK39 and SNAI1, 
respectively (Figure 3B). To identify the region in 





SNAI1 that associates with STK39, we generated two 
deletion mutants of SNAI1 [33,36]: the N-terminal 
SNAI1 (amino acids 1-153), which includes the SNAG 
domain of SNAI1; and the C-terminal SNAI1 (amino 
acids 153-265), which contains the conserved zinc 
finger motif (Figure S2A). The C-terminal region of 
SNAI1 was responsible for its interaction with STK39. 
We then co-expressed Myc-STK39 and GFP-SNAI1 in 
HEK293 cells. Surprisingly, STK39 stabilized SNAI1 
in the nucleus (Figure 3C). Although STK39 
predominantly localizes to cytosol, it contains a 
putative nuclear localization signal that enables 
nuclear translocation [25]. Since SNAI1 turnover is 
decreased in the nucleus, we asked whether 
stabilization of SNAI1 by STK39 might occur in 
nucleus and prevent its nuclear-cytosolic transport 
thereby leading to its stabilization. To test this 
possibility, we overexpressed STK39 in T-47D cells 
and fractionated the cells into cytosolic and nuclear 
fraction. SNAI1 protein was only detected in the 
nucleus and increased SNAI1 protein was 
predominantly nuclear in T-47D cells (Figure 3D). We 
then screened potential serine/threonine phos-
phorylation sites that may facilitate nuclear SNAI1 
retention. We co-expressed the WT and mutant 
SNAI1 with Myc-STK39 in HEK293T cells. STK39 
greatly enhanced the stabilization of WT, SNAI1- 
T177A, SNAI1-2SA, SNAI1-4SA, SNAI1-6SA [12], and 
SNAI1-8SA (SNAI1-6SA+S105A+S121A), which were 
resistant to degradation [12] but not T203A [19], 
which suggests that T203 is a potential target site for 
STK39 (Figure 3E). Consistent with this, STK39 
markedly increased the WT-SNAI1 protein levels but 
expression in SNAI1-T203A did not change 
significantly (Figure 3F). Moreover, using a specific 
antibody against phosphor-SNAI1 T203 (pT203- 
SNAI1) [19], we detected SNAI1 phosphorylation in 
HEK293T cells transfected with wild-type SNAI1, but 
not SNAI1 T203A (Figure 3G, lane 1 vs lane 3). In 
addition, the pT203-SNAI1 level was upregulated by 
STK39-WT but not STK39-KR (Figures 3G and S2B). 
Furthermore, endogenous pT203-SNAI1 was detected 
in MDA-MB-231 and MDA-MB-157 cells, whereas 
knockdown of STK39 dramatically decreased 
endogenous pT203-SNAI1 levels (Figure 3H). These 
results consistently indicate that STK39-mediated 
T203 phosphorylation results in SNAI1 stabilization 
by nucleus retention thus suppressing SNAI1 
degradation. 
STK39 enhances EMT in a SNAI1-dependent 
manner 
To explore the functional role of STK39, we 
expressed STK39 in two luminal breast cancer cell 
lines, MCF7 and T-47D. STK39 expression induced 
SNAI1 stabilization as well as downregulation of 
CDH1 in these cells (Figure 4A). Consistently, STK39 
expression induced a morphologic change indicative 
 
 
Figure 4. Overexpression of STK39 induces EMT. (A) STK39 was expressed in MCF7 and T-47D cells. A rescue experiment with knockdown of SNAI1 expression in 
WT-STK39 expressing cells was also performed. The levels of CDH1, SNAI1 and STK39 were analyzed by western blot. (B) STK39 was expressed in MCF7 cells. A rescue 
experiment with knockdown of SNAI1 expression was also performed. Morphologic changes indicative of EMT were shown in the phase-contrast images; expression of CDH1 
was assessed by immunofluorescent staining. Nuclei were visualized with DAPI (blue). (C) STK39 was expressed in MCF7 and T-47D cells. A rescue experiment with knockdown 
of SNAI11 expression was also performed. mRNA levels were quantitated by real-time PCR. Data are the mean±s.d. of two separate experiments in triplicates. (D) Boyden 
chamber migration assay of modified MCF7 and T-47D cells, as described in A. Data are the mean±s.e.m. (E) Boyden chamber invasion assay of modified MCF7 and T-47D cells, 
as described in A. Data are the mean±s.e.m. * P<0.05, ***P<0.01, *** P<0.001, compared with vector. 





of EMT (Figure 4B), accompanied with 
downregulation of CDH1. In addition, Real-time PCR 
revealed that STK39 expression downregulated 
epithelial markers (CDH1, CLDN3 and OCLN) and 
upregulated mesenchymal molecules Vimentin (VIM) 
(Figure 4C). Functionally, STK39 expression 
markedly enhanced the cell migration and invasive 
capacity (Figures 4D-4E, and S3). The catalytic 
activity of STK39 is required for these functions, 
because STK39-KR had no effect on SNAI1 
expression, the morphological changes, or cell 
migration and invasion in these cells (Figure 4 and 
S3). Importantly, knockdown of SNAI1 markedly 
attenuated these changes (Figures 4 and S3), 
indicating that the functional activities promoted by 
STK39 required SNAI1 upregulation. 
To further assess the function of STK39 in breast 
cancer, we established clones with STK39 knockdown 
in MDA-MB-231 and MDA-MB-157 cells. We 
achieved 80–90% knockdown efficiency of 
endogenous STK39 using two independent shRNAs 
(Figure 5A). For both clones, STK39-knockdown 
increased CDH1 levels and downregulated 
expression of N-cadherin (Figure 5A). Consistent with 
this, loss of STK39 significantly increased mRNA 
expression levels of epithelial markers (Figure 5B). 
Immunofluorescence analysis also suggested an 
upregulation of CDH1 and downregulation of 
N-cadherin (Figure 5C). STK39 knockdown greatly 
inhibited the migration and invasive capabilities of 
 
 
Figure 5. Knockdown of STK39 inhibits EMT, migration and invasion in breast cancer cells. (A) STK39 was knocked down by two different shRNAs in 
MDA-MB-231 and MDA-MB-157 cells. Rescued SNAI1 expression in the STK39-knockdown clone was also performed. The expression of CDH1, N-cadherin, STK39 and SNAI1 
was analyzed by western blot. SN: SNAI1. (B) STK39 was knocked down by two different shRNAs in MDA-MB-231 and MDA-MB-157 cells. Rescued SNAI1 expression in the 
STK39-knockdown clone were also performed. The mRNA levels of epithelial markers were quantitated by real-time PCR. Data are the mean ± SD of two separate experiments 
in triplicates. CLDN3, Claudin 3; OCLN; Occludin. (C) Immnofluorescent images of EMT markers in MDA-MB-231 and MDA-MB-157 cells described in (A). CDH1 (green); 
N-cadherin (red); DAPI (blue). (D) Graphic representation of cell motility described in (A) analyzed by a migration assay. Data are the percentage of vector control values (mean 
± SEM in three separate experiments in duplicates). (E) Graphic representation of cell invasion described in (A). Data are the percentage of vector control values (mean ± SEM 
in three separate experiments in duplicates). (F) MCF10A cells were transduced with control or shSTK39 lentiviruses. After selection in puromycin, cells were treated with 
TGF-β1 (2 ng/ml) for 2 days. The expression of CDH1, N-cadherin, STK39 and SNAI1 was analyzed by western blot. * P<0.05, **P<0.01, *** P<0.001. 





these cells (Figures 5D-5E, and S4). Rescued SNAI1 
expression in STK39-knockdown clones largely 
recovered the effects induced by STK39 ablation 
(Figures 5 and S4). The breast epithelial cells MCF10A 
were extensively used as a model to study the cellular 
EMT. As previously reported [19,37], TGF-β1 
treatment induced EMT and activated expression of 
SNAI1 in MCF10A cells (Figure 5F). Depletion of 
STK39 significantly inhibited EMT and SNAI1 
expression. Taken together, these results clearly 
suggest that STK39 enhances breast cancer metastasis, 
in large part, in SNAI1-dependent manner. 
STO phenocopies the effects of STK39 
deficiency 
Treatment with STO increased CDH1 expression 
and downregulated SNAI1 expression in a time- 
course (Figure 6A) and dose-dependent manner 
 
 
Figure 6. STK39 inhibitor phenocopies STK39 deficiency. (A) MDA-MB-231 and MDA-MB-157 cells were treated with STO 10 µM for different time intervals. 
Expression of endogenous CDH1 and SNAI1 were assessed by western blot. (B) MDA-MB-231 and MDA-MB-157 cells were treated with different doses of STO for 48 h. 
Expression of endogenous SNAI1 and STK39 were assessed by western blot. (C) MDA-MB-231 and MDA-MB-157 cells were treated with 10 µM STO for 48 h. The expression 
of CDH1, N-cadherin, and SNAI1 was analyzed by western blot. (D) Immunofluorescent images of EMT markers in MDA-MB-231 and MDA-MB-157 cell lines described in (C). 
(E) MDA-MB-231 and MDA-MB-157 cells were treated with 10 µM STO for 24 h. The mRNA levels of epithelial markers were quantitated by real-time PCR. Data are the mean 
± SD of two separate experiments performed in triplicates. CLDN3, Claudin 3; OCLN; Occludin. (F) MDA-MB-231 and MDA-MB-157 cells were treated with 10 µM STO for 
24 h and analyzed for cell migration. Representative imagines (upper panel) and graphic representation (lower panel) is the percentage of migration cells (mean ± SEM from three 
separate experiments in duplicates). (G) MDA-MB-231 and MDA-MB-157 cells were treated with 10 µM STO for 24 h and analyzed for cell invasion. Representative imagines 
(upper panel) and graphic representation (lower panel) is the percentage of invasive cells (mean ± SEM from three separate experiments in duplicate). STO, STOCK2S 26016 
(STK39 inhibitor); ** P<0.01, *** P<0.001, compared with DMSO control group. 





(Figure 6B). STO treatment also up-regulated CDH1 
levels and downregulated expression of N-cadherin 
(Figure 6C). Immunofluorescence analysis further 
revealed the increase of CDH1 and decrease of 
N-cadherin (Figure 6D). Consistent with STK39 
deficiency, treatment with STO upregulated epithelial 
markers (Figure 6E) and greatly inhibited the 
migration and invasion of these cells (Figures 6F-6G). 
In sum, treatment with a STK39 inhibitor phenocopies 
the effects observed with loss of STK39 expression; 
specifically these include impaired migration, SNAI1 
downregulation, and increased CDH1 expression, 
and thereby supports a critical role for STK39 kinase 
activity in EMT. 
Inhibition of STK39 sensitizes chemotherapy 
treatment and blocks metastasis in vivo 
SNAI1 is associated with acquisition of 
chemoresistance [38]. Paclitaxel (PTX) is the classical 
taxane, used in breast cancer therapy with efficacy in 
early and metastatic breast cancer [39]. Unfortunately, 
effective and successful therapy for patients is 
commonly limited by an acquired resistance. To test 
whether knockdown of STK39 enhances paclitaxel 
sensitivity, we determined the IC50 of PTX with or 
without depletion of STK39 in MDA-MB-231 and 
MDA-MB-157 cell lines. Loss of STK39 reduced the 
IC50 of PTX (Figure 7A). To determine whether STO 
has synergy with PTX, we treat the MDA-MB-231 and 
MDA-MB-157 cells with paclitaxel with or without 
STO treatment. STO acted synergistically with 
paclitaxel to suppress cell proliferation (Figure 7B). 
Soft agar colony formation analysis revealed that the 
combination treatment with STO and PTX resulted in 
a greater reduction in both colony formation and 
colony size when compared to paclitaxel alone 
(Figure 7C). Our data suggest that STK39 inhibition 
sensitizes breast cancer cells to PTX. 
To directly assess whether STK39 is critical for 
cell metastasis in vivo, we intravenously injected 
STK39-knockdown MDA-MB-231-luciferase cells into 
female SCID mice and subjected these mice to 
bioluminescent imaging (BLI). All control mice were 
moribund due to massive lung metastases (Figure 
7D). In contrast, mice injected with STK39- 
knockdown cells were viable and free of detectable 
metastases. Control cells exhibited a high number of 
metastatic lesions whereas STK39-knockdown cells 
lacked metastatic colonies by histologic analyses 
(Figures 7E-7F). In agreement with the function of 
SNAI1 in vitro, expression of exogenous SNAI1 in 
STK39-knockdown cells largely rescued the formation 
of lung metastasis (Figures 7D-7F). SNAI1 expression 
was inversely correlated with tumor-free survival in 
breast cancer [40]. To verify whether women with 
primary breast cancers that express a high level of 
STK39 relapse at a faster rate than women whose 
breast cancers express a low level of STK39, in a 
pattern similar to that of SNAI1, we analyzed two 
microarray expression datasets derived from primary 
human breast cancers in which both STK39 expression 
level and clinical outcome were available. 
Intriguingly, individuals with high STK39 expression 
had a reduced overall survival or interval of 
disease-free survival (Figure 7G). These results 
suggest that STK39 expression may represent an 
important prognostic indicator for breast cancer in the 
clinical setting. 
Discussion 
Our current study demonstrates that STK39 
stabilizes SNAI1 through phosphorylation at T203, 
which is critical for its nuclear retention. In addition, 
STK39 plays a critical role in tumor metastasis. More 
importantly, STK39 knockdown cells are more 
sensitive to chemotherapeutic treatment. Also, STK39 
expression correlates with poor survival of breast 
cancer patients. Therefore, our study not only 
uncovers a role for STK39 in breast cancer progression 
but also provides new insights into the regulation of 
SNAI1. 
SNAI1 stability is extensively regulated by 
phosphorylation. On one hand, phosphorylation of 
SNAI1 promotes its proteasomal-mediated 
ubiquitination degradation. For example, both CK1 
and DYRK2-mediated SNAI1 phosphorylation act as 
a prime phosphorylation that permits GSK3β- 
mediated phosphorylation, leading to β-TRCP- 
induced poly-ubiquitination and degradation [12,41]. 
PKD1-mediated phosphorylation of SNAI1 facilitates 
FBXO11-mediated SNAI1 degradation [42]. Under 
intact apical-basal polarity, aPKC kinases promote 
degradation through phosphorylation of SNAI1 S249 
[43]. Other phosphorylations of SNAI1 prevent its 
degradation. Most commonly, SNAI1 ubiquitination 
is blocked by reducing its affinity for GSK3β. For 
example, phosphorylation of SNAI1 by ATM and 
DNA-PKCs inhibits SNAI1 ubiquitination through 
reducing its interaction with GSK3β [20,22]. Recently, 
it was shown that p38 stabilizes SNAI1 through 
phosphorylation at Ser107, which suppresses 
DYRK2-mediaed Ser104 phosphorylation that is 
required for the GSK3β-mediated SNAI1 degradation 
[18]. Alternatively, SNAI1’s confinement in the 
nucleus prevents degradation. Both PI3K and PAK1 
phosphorylate SNAI1 on Ser246 to increase SNAI1’s 
accumulation in the nucleus [44,45]. ERK2-mediated 
Ser82/Ser104 phosphorylation of SNAI1 leads to 
SNAI1 nuclear accumulation [21]. Lats2 
phosphorylates SNAI1 at T203 in the nucleus, which 





prevents nuclear export, thereby supporting 
stabilization [19]. In this study, we found that STK39 
also enhances SNAI1 stability by its phosphorylation 
at T203. Notably, Lats2 directs its association at the 
N-terminal region (aa 10-40) of SNAI1 [19] whereas 
STK39 interacts with C-terminal region which harbors 
T203, raising the potential that Lats2 and STK39 can 
simultaneously interact with and phosphorylate 
SNAI1 at T203. STK39 promotes SNAI1 stability by 
blocking protein degradation but does not decrease its 
poly-ubiquitination (data not shown). We also noticed 
that STK39 did not impair the interaction between 
GSK3β and SNAI1. A plausible explanation for this 
confounding observation could be that STK39 
phosphorylates SNAI1 at T203 promoting 
accumulation in the nucleus, whereas the GSK3β- 
degradation components are cytoplasmic. However, 
the precise molecular mechanisms for the T203 
phosphorylation-mediated SNAI1 stability remain to 
be fully elucidated. 
 
 
Figure 7. Inhibition of STK39 sensitizes cancer cells to PTX treatment and suppresses tumor metastasis in vivo. (A) MDA-MB-231 and MDA-MB-157 cells were 
transfected with control vector or STK39 shRNA to identify the IC50 of paclitaxel. (B) MDA-MB-231 and MDA-MB-157 cells were treated with 5 µM STO or 1µM PTX alone, 
or in combination for different time periods and cell proliferation was determined. (C) Cells were treated with DMSO, 5 µM STO or 1 µM PTX alone, or in combination for 24 
h. Washed cells were plated in soft agar and cultured for 10-12 days. Colonies were fixed, stained and photographed. Presented data are the mean ± SD from three independent 
experiments. (D) MDA-MB-231-luc cells transfected with control, STK39 shRNA or STK39-knockdown cells with SNAI1 rescued expression were injected through tail vein into 
female SCID mice. Lung metastasis was assessed by bioluminescence imaging. Images are representative of each experimental group. SN, SNAI1. (E) Representative images of 
lung lesions (upper panel) and H&E stained lung sections (lower panel) from experimental groups in (D). (F) Lung nodule number from experimental groups in (D). (G) 
Kaplan-Meier plots of distant metastasis-free survival or overall survival of patients, stratified by expression of STK39. Data obtained from the GSE1456 and GSE3494 database. 
STO, STOCK2S 26016 (STK39 inhibitor); PTX, paclitaxel. * P<0.05, *** P<0.001, compared with control. 





Multiple studies showed that STK39 plays key 
roles in regulating cellular ion homeostasis and blood 
pressure through activation of NCC and NKCC2 [30]. 
STK39 also increases colonic epithelial permeability 
and pro-inflammatory cytokines, and STK39 
knockout mice lack intestinal and renal inflammation 
and pro-inflammatory cytokine secretion compared to 
control mice [27,46]. However, recent studies identify 
functions in cancer progression as well. Reports 
demonstrated that STK39 expression was significantly 
increased in non-small lung cancer cells, and 
expression was positively associated with advanced 
tumor staging, lymph node metastasis and poor 
prognosis [29]. However, the underlying mechanism 
was unknown. It was also reported that STK39 was 
necessary for proliferation but not for endothelial cells 
migration [47]. Our studies clearly showed that STK39 
controls EMT by stabilizing the CDH1 repressors of 
SNAI1 and is crucial for migration in breast cancer. 
Accordingly, loss of STK39 expression inhibited the 
migration and invasion of cells in vitro and metastasis 
in vivo. Therefore, our study not only clearly confirms 
the role of STK39 in tumor metastasis but also reveals 
the underlying molecular mechanism. Notably, 
STK39 protein levels did not correlate with the SNAI1 
protein expression in breast cancer cell lines and 
breast cancer tissues (data not shown) because the 
activity of STK39 need to be activated. However, no 
suitable marker is available to detect the STK39 
activation. 
Because of its unique structural organization and 
important roles in regulating blood pressure, kidney 
disease, and cancer, STK39 is an active drug target 
that may hold future promise. Indeed, compounds 
that inhibit STK39 activity have been developed and 
show promise as a potential anti-cancer drugs [48-50]. 
STOCK2S 26016 (STO), a novel compound developed 
by high-throughput screening, inhibits STK39 
activation by reproducibly disrupting the binding of 
WNK to STK39 [51]. We found that STO phenocopied 
the effect of STK39 deficiency and inhibited cancer cell 
migration and invasion in vitro. In addition, the 
combined administration of STOCK and paclitaxel 
produced a synergistic therapeutic effect. However, 
there are no clinically-approved drugs that target 
STK39 being used to treat cancer. The 
pharmacokinetics and pharmacodynamics of STOCK 
are unknown [24]. Additional investigations are 
required to initiate live animal experiments, and then 
examine use clinically. Such action would offer 
synergistic effects with chemotherapy treatment on 
human breast cancer treatment. 
In summary, our study unveils a mechanism by 
which STK39 promotes EMT and the metastasis of 
tumor cells by enhancing the stability of SNAI1. Our 
study extended the multifaceted role STK39 in human 
disease from that of a key regulator of hypertension to 
a key metastasis promoter. Our study also has 
important implication for the development of 
STK39-based targeting strategies for metastatic 
cancers. 
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